(Updated - October 16, 2017 10:41 AM EDT)

(updated to add analyst comments)Needham & Company raised its price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments Momentum Movers

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson HumphreyOctober 16, 2017 11:16 AM Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaOctober 16, 2017 7:03 AM Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell CarcinomOctober 16, 2017 7:00 AM Exelixis (EXEL) Reports Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall SurvivalOctober 16, 2017 6:59 AM Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell CarcinomaOctober 16, 2017 6:59 AM